Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) shed more than half of its value on Thursday as it warned that audited results for the year to June 2022 would not be ready by the end of this year.
“Consequently, the shares of the company will be suspended from trading from 7.30 am on 3 January 2023,” it said in a statement.
Preliminary results for the year in question were released on 29 September and Allergy added it is not aware of any material change that will be required to be made, adding it is "actively working to finalise the audit and publication of its annual report and accounts".
Allergy reiterated it is also actively reviewing all funding options following a voluntary pause in production that has led to the need for significant additional near-term funding.
Production at its Worthing allergy products facility was halted at the start of October before resuming again on 14 November, around seven weeks’ worth of lost production.
Shares fell 56% to 5p.